The medical rise of GLP-1 analogues: background, discoveries and promise
The discovery of GLP-1 (glucagon-like peptide-1), an essential intestinal hormonal messenger in the management of glycemia and eating behavior, came to light in the late 1980s. This substance, released by the digestive tract just after food ingestion, stimulates insulin production while curbing glucagon production. Pioneers such as Daniel Drucker, Joel Habener and Jens Juul Holst were quick to highlight its therapeutic potential in the face of rising obesity and type 2 diabetes.
On a global scale, the World Health Organization is sounding the alarm about the rapid increase in overweight: according to the latest estimates, more than 650 million adults are affected. As a result, the trajectory of GLP-1 has taken on a new dimension, thanks to major biotechnological advances. Injectable analogues, such as Ozempic, Wegovy or Mounjaro, originally designed for diabetics, are now at the center of many medical debates – and some queues outside pharmacies, testifying to a craze that goes beyond the strict medical indication.
A key distinction separates biologically-derived GLP-1 from its pharmaceutical equivalents: while the hormone acts with meals, copycat drugs prolong this effect through regularly scheduled injections. Daniel Drucker and his colleagues, whose work has been recognized with a Gairdner Prize in 2021, symbolize this scientific breakthrough. It’s worth noting that, behind this feat, a host of international researchers have also been involved – from hospital centers in Bordeaux to the Heinrich Heine Düsseldorf, via the fledgling University of Valparaíso.
Novo Nordisk, with its Ozempic/Semaglutide and Wegovy molecules, is leading the way in this race for innovation – backed by major health authorities and growing demand in France too. Between the multiplication of publications, the tensions on global supplies observed since 2023 and the multiplication of off-label prescriptions, we measure the clinical success, but also the challenges: financing by healthcare systems, debate on the broadening of targets (cardiovascular prevention, NASH – non-alcoholic steatohepatitis).
Faced with a chronic disease like obesity, now recognized for its complexity by the French National Health Insurance Fund, therapeutic alternatives around GLP-1 are turning old practices upside down, but also questioning equity of access to this breakthrough. In some university hospitals (such as Amiens and Toulouse), multidisciplinary teams are seeing a new generation of patients – some of whom have come after trying to obtain the drug outside the official circuit.
Consult recommended sources for tracking GLP-1 therapies and, if possible, field feedback from practicing dietitians.
Mode of action and benefits: a revolution in weight management and comorbidities
GLP-1-related therapies act by reproducing the physiological impulse of the natural hormone after meals, but in a more sustained and long-lasting version. Their mechanism, at once sophisticated and formidably effective, comprises several dimensions:
Amplification of insulin secretion (incretinic effect) to control blood sugar levels.
Blocking of glucagon, limiting hepatic glucose production.
Slowing of gastric transit, prolonging the sensation of satiety.
Effect on the brain’s reward and sweet craving zones.
Clinical trials confirm a breakthrough; some results have surprised even the most experienced teams: around 10 to 15% weight reduction in one year for overweight or obese subjects, well above the 5% obtained with conventional lifestyle-focused strategies. This gain is most often accompanied by a drop in cardiovascular risk and an overall improvement in associated metabolic disorders.
The following comparative table highlights this far-reaching change:
| Aspect | Classical approaches (diet/exercise) | GLP-1 analogues (Ozempic, Wegovy, Mounjaro) |
|---|---|---|
| Weight loss (12 months) | 3-6% | 10-15% |
| Action on satiety | Moderate | Marked (stomach action, central action) |
| Decreased sweet appetite | Small | Often significant |
| Improved CV | Variable | Benefits demonstrated in certain profiles |
| Modality of administration | Non-drug | Weekly or daily injection |
| Side effects | Minor (frustration, weight regain) | Frequent digestive, rare serious complications |
Beyond the impact on weight, the reduction of cardiovascular events in type 2 diabetics is the subject of international consensus. Some patients, followed up in specialized clinics in Montpellier or Limoges, for example, describe the rediscovery of food pleasure differently: “It’s not so much that I don’t crave sugar anymore, it’s that I think about it less”, they confide after several months of treatment.
Research is now exploring new horizons: treatment of NASH, potential prevention of certain diseases such as Alzheimer’s, understanding complex eating behaviors and food pleasure. The notion of multi-causality, long neglected (genetic issues, social influences, reward psychology, environmental exposome), is making a comeback. Patient experience, sometimes in tension with expert discourse, becomes a valuable tool for adjusting follow-up.
Clinical studies are helping to better appreciate the efficacy of GLP-1 analogues, but feedback from the field also suggests sometimes chaotic health pathways, particularly in disadvantaged contexts.
Our opinion: a major innovation, but not a panacea
The massive emergence of GLP-1-fed treatments marks a turning point, both for medicine and for society. Nevertheless, to present these solutions as the universal cure for obesity would be excessive. The history of recent pharmacology – with the examples of Isomeride and Mediator – reminds us that every advance calls for a certain caution: long-term safety, equitable distribution and even the impact on the social environment remain in question. And while GLP-1 redefines the balance between drug-based solutions and innovative prevention strategies, the need for comprehensive support, ranging from nutritional approaches to psychological support, has not disappeared. Moreover, the temptation of “express weight loss” should not make us forget the impact of social and environmental determinants, nor the long road of prevention in public health.
There is a persistent ethical tension: the pharmaceutical sector, a driver of innovation, also raises questions about cost, equity and the risk of medical dependency. Over the years, many patient experts and associations have called for a more humane approach, but the dissonance between prevention and medicalization persists in public debate.
The clinical and social reality behind the “miracle”: indications, limitations and patient profiles
The use of GLP-1 drugs relies on precise selection and collaborative follow-up. Distinguishing medical eligibility, prescribing dynamics and access issues is therefore essential.
The indications mainly target people with:
A BMI over 30, or over 27 if there is at least one associated chronic disease (diabetes, hypertension, sleep apnea…).
Duly established failure of non-drug measures over time.
The proposed solutions are weekly (Semaglutide/Ozempic, Tirzepatide/Mounjaro) or daily (Liraglutide/Saxenda) subcutaneous injections.
The monthly cost is in the region of €300, which is not reimbursed in France, but only as part of a weight-loss strategy with no other indication. Clearly, this question of cost creates strong inequalities, and some patients report having had to organize themselves, sometimes via the black market, to follow their treatment – a worrying phenomenon.
The transversal approach – nutrition, tailored physical activity, behavioral support – remains at the heart of effectiveness; it’s not enough to rely on a single therapeutic lever.
New tensions are emerging around uses outside the defined framework:
Clandestine trade and high circulation on the Internet, exposing trafficking and illicit formulations. This black market, observed even in WhatsApp groups or specialized forums, complicates risk management.
Diversion for purely aesthetic purposes, beyond any objective criteria.
Reinforced stigmatization of overweight: some patients feel both marginalized and destabilized by these discourses on the “miracle solution”, with the risk of increasing already existing inequalities.
In some university hospitals, such as Amiens or Bordeaux, the treatment pathway is based on consultation between doctor, dietician and sometimes patient-expert – an approach that remains far from the norm everywhere. Practicing dieticians regularly testify to the difficulty of maintaining therapeutic compliance over time, especially after the initial phase of enthusiasm.
Systematically check official access criteria by consulting your reference sources.
Side effects and vigilance: from clinical monitoring to public pharmacovigilance
The adverse effects profile of GLP-1-based treatments is now clearly documented.
The most frequent reactions involve the digestive system: nausea (up to 40% of users), vomiting, diarrhea, slowed transit, constipation.
Muscular wasting, or sarcopenia, can occur when weight loss is too rapid, especially in vulnerable subjects; specialized dietary support then remains crucial (physical activity protocols are sometimes set up in specialized clinics).
Other rare but serious complications include acute pancreatitis, psychiatric disorders (notably the appearance of depressive symptoms or suicidal ideation), and some long-term concerns about the possible development of cancers with prolonged use.
Attentive medical monitoring becomes almost indispensable, especially as on stopping, almost 75% of users regain a large proportion of the weight lost if overall supervision is not continued. This reversal is sometimes observed in less than two years; several patients mention this “rebound effect” which is difficult to live with, particularly after stopping the drug out of choice or financial necessity.
The surveillance authorities (ANSM in France, EMA in Europe, WHO worldwide) are multiplying their warnings: the need to entrust prescribing only to trained professionals, and the active fight against the black market and counterfeit versions.
The CRPV (pharmacovigilance) network regularly relays adverse effects and cases of over-the-counter use, but the dynamics of the underground market (non-compliant products or products bought online) complicate monitoring. Occasionally, the Caisse Nationale d’Assurance Maladie will intervene in the event of serious complications.
For any start-up or discontinuation of this type of treatment, get scrupulous information from official organizations and reliable sources – feedback from patients themselves is also a mine of information for adapting support.
Towards a new approach to the fight against obesity: innovation, limits and prospects
In many respects, GLP-1 analogues embody a decisive step forward for public health. However, the temptation to over-medicalize the response to obesity – sometimes to the detriment of classic preventive measures – is not without risk. It would be a pity if the focus on weight loss through medication were to overshadow the fight against inequalities, the promotion of prevention and the consideration of individual care pathways.
From the patient’s point of view, the reality is sometimes harsher than advertised: the promised multidisciplinarity remains uneven, and therapeutic compliance (adherence to the protocol, over years) raises questions – a practitioner at the Université de Picardie Jules Verne confides that some give up for lack of regular follow-up or appropriate support, while others organize themselves on forums. It seems that the role of expert patients, or real-life feedback, is gaining in importance to better understand what “sustainable weight loss” means on the ground.
The pharmaceutical sector is proposing revolutions, but the question remains: how to forge a balanced strategy that guarantees access to treatments, reinforces prevention, secures the patient against the black market, and is part of an ethical and humanistic approach? The issue of cost, reimbursement, the extension of uses and the maintenance of comprehensive support, truly adapted to the field, remains unavoidable and will inevitably be at the heart of debates in the face of the rising epidemic.
GLP-1, finally, holds its place among the great promises provided that we never dissociate innovative method, solid prevention and real health equity – a matter of balance more than miracle.
Participate in the debate on the balance between innovation, prevention and accessibility in public health. Contact your dietician or a specialized center for concrete information, especially if tempted to buy outside the network.
